HPM Partners LLC grew its holdings in Becton Dickinson and Co (NYSE:BDX) by 106.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,159 shares of the medical instruments supplier’s stock after purchasing an additional 5,238 shares during the period. HPM Partners LLC’s holdings in Becton Dickinson and were worth $2,175,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in the business. Wendell David Associates Inc. increased its stake in Becton Dickinson and by 1.3% in the fourth quarter. Wendell David Associates Inc. now owns 17,107 shares of the medical instruments supplier’s stock worth $3,662,000 after purchasing an additional 225 shares during the period. Pacer Advisors Inc. increased its stake in Becton Dickinson and by 4.9% in the third quarter. Pacer Advisors Inc. now owns 5,043 shares of the medical instruments supplier’s stock worth $988,000 after purchasing an additional 234 shares during the period. Waldron LP increased its stake in Becton Dickinson and by 16.6% in the fourth quarter. Waldron LP now owns 1,818 shares of the medical instruments supplier’s stock worth $389,000 after purchasing an additional 259 shares during the period. Aristotle Capital Management LLC increased its stake in Becton Dickinson and by 21.6% in the fourth quarter. Aristotle Capital Management LLC now owns 1,459 shares of the medical instruments supplier’s stock worth $312,000 after purchasing an additional 259 shares during the period. Finally, Dowling & Yahnke LLC increased its stake in Becton Dickinson and by 3.4% in the fourth quarter. Dowling & Yahnke LLC now owns 8,108 shares of the medical instruments supplier’s stock worth $1,736,000 after purchasing an additional 270 shares during the period. Institutional investors and hedge funds own 83.37% of the company’s stock.
In related news, VP John E. Gallagher sold 5,346 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $226.08, for a total transaction of $1,208,623.68. Following the sale, the vice president now owns 9,391 shares of the company’s stock, valued at $2,123,117.28. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Timothy M. Ring sold 176 shares of the firm’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $218.27, for a total value of $38,415.52. Following the sale, the director now directly owns 170,688 shares in the company, valued at approximately $37,256,069.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 279,231 shares of company stock worth $60,895,317. 1.00% of the stock is owned by corporate insiders.
Shares of Becton Dickinson and Co (BDX) opened at $226.12 on Monday. Becton Dickinson and Co has a 12-month low of $175.66 and a 12-month high of $248.39. The firm has a market capitalization of $60,202.75, a PE ratio of 172.61, a P/E/G ratio of 1.64 and a beta of 1.18. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter last year, the company earned $2.33 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. equities analysts expect that Becton Dickinson and Co will post 10.94 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s payout ratio is currently 229.01%.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.